Reinforcement of the Impact of a Functional Insulin Therapy Training Course by Telemonotoring With a PDA-phone in Type 1 Diabetic Patients. The TELFIT Study Patients

Phase 3

Completed

• Conditions: Type 1 Diabetes Mellitus
• Interventions: Device: PDA-phone + telemonitoring; Device: paper support

• Registration Number: NCT00758082
• Lead Sponsor: University Hospital, Grenoble

Brief Summary

TELFIT is a monocenter, controlled, randomised trial. It focuses on type 1 diabetes patients that have attended a functional insulin therapy training course. The Primary objective of the TELFIT study is to evaluate whether a PDA with telemonitoring by phone reinforces the effects of the functional insulin therapy training course as compared with conventional care.

Main judgment criteria: comparison of HbA1c means between M0 (start) and M3(3 months)

Detailed Description

All patients will attend a functional insulin therapy training course and be randomized into 2 groups. One group will receive a PDA-phone and one month of phone consultations with a nurse and a physician. The other group will only have the usual paper support. This study compares the evolution of HbA1c in the 2 groups over a period of 3 months. It also assesses time spent by nurses and physicians, changes in quality of life, hypoglycaemia frequency and weight changes.

Study Timeline

• Study Start: 2008-07
• Study First Submitted: 2008-09-19
• Study First Submitted QC: 2008-09-22
• Study First Posted: 2008-09-23
• Status Verified: 2010-03
• Primary Completion: 2010-03
• Study Completion: 2010-03
• Last Update Submitted: 2010-03-10
• Last Update Posted: 2010-03-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 62

Inclusion Criteria

• Type 1 diabetes mellitus for ≥ 6 months or more
• Age > 18 year old
• The patient has attended a functional insulin therapy class or workshop
• Insulin basal-bolus therapy for at least 6 months. At inclusion, patients should be treated either with a long-acting insulin and insulin rapid analog before each meal, or with rapid insulin analog delivered with a pump
• Ability to understand how the PDA-phone works and ability to use it
• Social Security membership or benefit from Social Security
• Patients equipped with a memory blood glucose monitor
• Informed consent, with a signed and approved form

Exclusion Criteria

• Underage patient, major patient under guardianship or protected by the Law
• Patient with any unstable associated evolutive pathology that could cause a diabetes imbalance within the coming year
• Change in diabetes treatment within the 3 months before inclusion or planned during the study
• Patient who needs a more frequent diabetic follow-up than in the protocol (especially severe or evolving complication due to diabetes)
• Patient attending another education program within the 3 months before inclusion or planning to attend one during the study
• Patient with toxicomania, alcoholism or psychological troubles that could impact the study
• Type-2-diabetic patient
• Patient who doesn't need strict metabolic objectives
• Pregnant or possibly pregnant woman
• Person with no freedom (prisoner)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
2	PDA-phone + telemonitoring	PDA-phone + phone consultations + standard visit at 3 months
1	paper support	Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support

Primary Outcome Measures

Name	Time	Method
Comparison of HbA1c means	M0 (start) and M3 (3 months)

Secondary Outcome Measures

Name	Time	Method
Difference between theoretical insulin dose and actual dose, one week before the 3-month reevaluation session	M0 (start) and M3 (3 months)
DHP scale of quality of life and satisfaction dimension of the DQOL questionnaire	M0 (start) and M3 (3 months)
Time spent by physicians and nurses in the different groups	M0 (start) and M3 (3 months)
Weight changes during the 3-month period	M0 (start) and M3 (3 months)
Number of hypoglycemias (moderate and severe) during the 3-month period	M0 (start) and M3 (3 months)

Trial Locations

Locations (1)

University Hospital Grenoble; 🇫🇷 Grenoble, France